EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

How Does HDL Participate in Atherogenesis? Antioxidant Activity Versus Role in Reverse Cholesterol Transport

Paul N Durrington iD, Bilal Bashir iD, Handrean Soran

Antioxidants · 02.04.2025 · 14 (4) · 430

DOI: 10.3390/antiox14040430 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antioxidants, online erschienen am 02.04.2025. Verfasst von Paul N Durrington und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Biology, Medicine and Health, Cardiovascular Research Group, University of Manchester, Manchester M13 9NT, UK. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Low-density lipoprotein (LDL) chemically modified by reactive oxygen species (ROS), for example, leaking from red blood cells in the vascular compartment, more readily crosses the vascular endothelium than does nonoxidatively modified LDL to enter tissue fluid. Oxidatively modified LDL (oxLDL) may also be created in the tissue fluid by ROS leaking from cells by design, for example, by inflammatory white cells, or simply leaking from other cells as a consequence of oxygen metabolism. As well as oxLDL, glycatively modified LDL (glycLDL) is formed in the circulation. High-density lipoprotein (HDL) appears capable of decreasing the burden of lipid peroxides formed on LDL exposed to ROS or to glucose and its metabolites. The mechanism for this that has received the most attention is the antioxidant activity of HDL, which is due in large part to the presence of paraoxonase 1 (PON1). PON1 is intimately associated with its apolipoprotein A1 component and with HDL’s lipid domains into which lipid peroxides from LDL or cell membranes can be transferred. It is frequently overlooked that for PON1 to hydrolyze lipid substrates, it is essential that it remain by virtue of its hydrophobic amino acid sequences within a lipid micellar environment, for example, during its isolation from serum or genetically modified cells in tissue culture. Otherwise, it may retain its capacity to hydrolyze water-soluble substrates, such as phenyl acetate, whilst failing to hydrolyze more lipid-soluble molecules. OxLDL and probably glycLDL, once they have crossed the arterial endothelium by receptor-mediated transcytosis, are rapidly taken up by monocytes in a process that also involves scavenger receptors, leading to subendothelial foam cell formation. These are the precursors of atheroma, inducing more monocytes to cross the endothelium into the lesion and the proliferation and migration of myocytes present in the arterial wall into the developing lesion, where they transform into foam cells and fibroblasts. The atheroma progresses to have a central extracellular lake of cholesteryl ester following necrosis and apoptosis of foam cells with an overlying fibrous cap whilst continuing to grow concentrically around the arterial wall by a process involving oxLDL and glycLDL. Within the arterial wall, additional oxLDL is generated by ROS secreted by inflammatory cells and leakage from cells generally when couplet oxygen is reduced. PON1 is important for the mechanism by which HDL opposes atherogenesis, which may provide a better avenue of inquiry in the identification of vulnerable individuals and the provision of new therapies than have emerged from the emphasis placed on its role in RCT.

Schlagwörter

Stichwörter der Autor:innen

LDLantioxidantatherosclerosiscardiovascular diseasehigh density lipoproteinlipid peroxidationparoxonase1

Autor:innen und Institutionen

  • Faculty of Biology, Medicine and Health, Cardiovascular Research Group, University of Manchester, Manchester M13 9NT, UK.
  • Department of Diabetes, Endocrinology and Metabolism, Peter Mount Building, Manchester University NHS Foundation Trust, Manchester M13 9WL, UK.

ORCID-Profile: Paul N Durrington, Bilal Bashir

Zitieren

APA

Durrington, P. N., Bashir, B., & Soran, H. (2025). How Does HDL Participate in Atherogenesis? Antioxidant Activity Versus Role in Reverse Cholesterol Transport. Antioxidants, 14(4), 430. https://doi.org/10.3390/antiox14040430

Vancouver

Durrington PN, Bashir B, Soran H. How Does HDL Participate in Atherogenesis? Antioxidant Activity Versus Role in Reverse Cholesterol Transport. Antioxidants. 2025;14(4):430. doi:10.3390/antiox14040430

BibTeX
@article{Durrington2025,
  author = {Durrington, Paul N and Bashir, Bilal and Soran, Handrean},
  title = {How Does HDL Participate in Atherogenesis? Antioxidant Activity Versus Role in Reverse Cholesterol Transport},
  journal = {Antioxidants},
  year = {2025},
  volume = {14},
  number = {4},
  pages = {430},
  doi = {10.3390/antiox14040430}
}
Kostenlos starten →